The European Commission has extended the authorisation of MenQuadfi: the quadrivalent meningococcal conjugate vaccine may now be used in the European Union in infants from six weeks of age. The previous EU authorisation covered individuals aged twelve months and older.
Protection against four meningococcal serogroups
MenQuadfi is indicated for active immunisation against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W and Y. The extended indication gives healthcare professionals an additional vaccination option for infant care.
Early access requires reliable procurement
An expanded indication changes demand, stocking and ordering requirements. Pharmacies, pharmaceutical wholesalers and other supply partners therefore need transparent availability data and reliable sourcing routes at an early stage.
tiger.PHARMA supports optimised MenQuadfi procurement – from market and availability checks to suitable sourcing routes and structured coordination with wholesalers and supply partners.
For specific availability and procurement enquiries, contact 247@tiger-pharma.com. Use is subject to the approved product information and applicable vaccination recommendations and should be managed by healthcare professionals.